InvestorsHub Logo

cabel

12/13/14 11:47 AM

#82281 RE: faxedreceipts #82269

Even if tingling occurs,.. I would take that over then side-effects of Daptopycin any day!

TheHound

12/13/14 12:08 PM

#82286 RE: faxedreceipts #82269

We're not sure if it has been "addressed". That info from the Ph 2b hasn't been released yet. We do know there were no SAE's related to B.

F1ash

12/13/14 12:18 PM

#82288 RE: faxedreceipts #82269

I imagine the numbness and tingling will still be there. It was prevalent in the first Phase 2 trial. It is just not a severe event.



"All three Brilacidin treatment arms (two single-dose regimens and one three-day dose regimen) reached the primary endpoint, with the clinical success rate for each dosing regimen statistically comparable to the clinical success rate of the FDA-approved seven-day dosing regimen of daptomycin. All Brilacidin treatment regimens were well tolerated. There were six severe adverse events (SAE) reported across the study, none of which were considered related to Brilacidin by the principal investigator" - See more at: http://cellceutix.com/brilacidin/#sthash.4fdwlJiV.dpuf

alwaysdreaming

12/13/14 2:00 PM

#82298 RE: faxedreceipts #82269

Bottom line data will address that I'm sure.